Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2011

Lee Hwa Jin, Wall Brian A, Wangari-Talbot Janet, Shin Seung-Shick, Rosenberg Stephen, Chan Joseph L-K, Namkoong Jin, Goydos James S, Chen Suzie

Abstract excerpt

PURPOSE: Melanoma is a heterogeneous disease where monotherapies are likely to fail due to variations in genomic signatures. B-RAF inhibitors have been clinically inadequate but response might be augmented with combination therapies targeting multiple signaling pathways. We investigate the preclinical efficacy of combining the multikinase inhibitor sorafenib or the mutated B-RAF inhibitor PLX4720 with riluzole,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Glutamic Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyridines

Share to Receptors, Metabotropic Glutamate

Share to Sorafenib

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 21844014
DOI: 10.1158/1078-0432.CCR-11-0098
PMCID: PMC3218300

Genes

GRM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.PMID 21844014Read ↗

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.Semantic proximity Read ↗

Riluzole is a radio‐sensitizing agent in an in vivo model of brain metastasis derived from <scp>GRM</scp>1 expressing human melanoma cellsSemantic proximity Read ↗

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.Semantic proximity Read ↗

Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.Semantic proximity Read ↗

Glutamate receptors: emerging players in melanomagenesis.Semantic proximity Read ↗

Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate.Semantic proximity Read ↗

Augmenting MEK inhibitor Efficacy in BRAF Wild-Type Melanoma: Synergistic Effects of Disulfiram Combination TherapySemantic proximity Read ↗

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.Semantic proximity Read ↗

Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.Semantic proximity Read ↗

Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.Semantic proximity Read ↗

Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma.Semantic proximity Read ↗

NMDA Receptor-Mediated Signaling Pathways Enhance Radiation Resistance, Survival and Migration in Glioblastoma Cells—A Potential Target for Adjuvant RadiotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.